Mahkam Zanganeh, Co-Chief Executive Officer, 10% Owner at Summit Therapeutics Inc. (SMMT), bought 100,000 shares at $14.60 ($1.5M) on 2026-06-04, disclosed to the SEC on 2026-06-04.
CEO Mahkam Zanganeh executed the largest insider purchase in Summit Therapeutics' history by buying $1.46M worth of shares, signaling confidence in the company's valuation. This move coincides with the stock trading near its 52-week low of $13.83, offering a potential entry point for contrarian traders.
The stock is currently trading at $16.12, down 17.59% over the past year and sitting 16.56% above its 52-week low of $13.83. Despite a flat performance over the last 30 days, the shares remain significantly undervalued relative to their 52-week high of $30.98.
Nothing distinguishes this filing.
| Filing → |
| SMMT | BUY | 2025-09-11 | $11.9M | — | Filing → |
| SMMT | BUY | 2024-03-27 | $539K | — | Filing → |
| SMMT | BUY | 2023-12-13 | $10K | — | Filing → |